(E)-1-[3',5'-DIMETHOXY-4'-[(ISOPROPYL)-OXY]-PHENYL]-2-[(2'',3''-DI-[(TERT.-BUTYLDIMETHYLSILYL)-OXY]-4''-METHOXY)-PHENYL]-ETHENE
Compound with spectra: 1 NMR
![(E)-1-[3',5'-DIMETHOXY-4'-[(ISOPROPYL)-OXY]-PHENYL]-2-[(2'',3''-DI-[(TERT.-BUTYLDIMETHYLSILYL)-OXY]-4''-METHOXY)-PHENYL]-ETHENE](/api/compound/3jRG3BLGBrX.png?ph=true&h=300&w=458 "(E)-1-[3',5'-DIMETHOXY-4'-[(ISOPROPYL)-OXY]-PHENYL]-2-[(2'',3''-DI-[(TERT.-BUTYLDIMETHYLSILYL)-OXY]-4''-METHOXY)-PHENYL]-ETHENE")
| SpectraBase Compound ID | 3jRG3BLGBrX |
|---|---|
| InChI | InChI=1S/C32H52O6Si2/c1-22(2)36-29-26(34-10)20-23(21-27(29)35-11)16-17-24-18-19-25(33-9)30(38-40(14,15)32(6,7)8)28(24)37-39(12,13)31(3,4)5/h16-22H,1-15H3/b17-16+ |
| InChIKey | VXAIZEZWQSKZPX-WUKNDPDISA-N |
| Mol Weight | 588.9 g/mol |
| Molecular Formula | C32H52O6Si2 |
| Exact Mass | 588.330242 g/mol |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | CDCl3 |
2,3-DI-[(TERT.-BUTYLDIMETHYLSILYL)-OXY]-4-(METHOXYBENZYL)-TRIPHENYLPHOSPHONIUM_BROMIDE
(Z)-(3,4,5-TRIMETHOXY)-(2'-ISOPROPYLOXY-3'-[PARA-TOLUENESULFONYLOXY])-STILBENE;MAJOR_ISOMER
(E)-(3,4,5-TRIMETHOXY)-(2'-ISOPROPYLOXY-3'-[PARA-TOLUENESULFONYLOXY])-STILBENE;MINOR_ISOMER
(E)-1-[3,4,5-tris(benzyloxy)phenyl)-3-[2,4-bis(benzyloxy)-6-(tert-butyldimethylsilyloxy)phenyl]propene
3-(3,4-dimethoxyphenyl)-7,8-dimethoxy-2H-1-benzopyran
Eusiderin E
(7S,8S)-SYRINGYLGLYCEROL-8-O-4'-SINAPYLETHER-9'-O-BETA-D-GLUCOPYRANOSIDE
SODIUM_3,4-METHYLENEDIOXY-5,4'-DIMETHOXY-3'-(L-TYROSYL)-AMIDO-Z-STILBENE-3'-O,N-(ALPHA)-DIPHOSPHATE
trimethylsilyl 3-[3-methoxy-5-[3-methoxy-5-(3-oxo-3-trimethylsilyloxy-prop-1-enyl)-2-trimethylsilyloxy-phenyl]-4-trimethylsilyloxy-phenyl]prop-2-enoate
| Title | Journal or Book | Year |
|---|---|---|
| Development of Synthetic Methodology Suitable for the Radiosynthesis of Combretastatin A-1 (CA1) and Its Corresponding Prodrug CA1P | Journal of Natural Products | 2009 |